ARPO Aerpio Pharmaceuticals Inc.

0.98
+0.01  (+1%)
Previous Close 0.97
Open 0.98
Price To Book 0.68
Market Cap 39906126
Shares 40,588,004
Volume 167,548
Short Ratio
Av. Daily Volume 652,757

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b trial to be initiated 1H 2019.
AKB-4924 (GB004)
Ulcerative Colitis
Phase 2 data released March 18, 2019 did not meet primary endpoint.
AKB-9778 - TIME 2B
Non-Proliferative Diabetic Retinopathy
Phase 1 ongoing.
GB004
Inflammatory bowel disease (IBD)
Phase 1b trial to be initiated 2Q 2019.
AKB-9778
Open angle glaucoma

Latest News

  1. Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Buy: What Does It Mean for the Stock?
  2. Aerpio Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
  3. Aerpio Pharmaceuticals stock plummets after failed trial of diabetic retinopathy treatment
  4. Greater Cincinnati pharma firm’s stock plummets
  5. Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy
  6. Aerpio Pharmaceuticals Inc (ARPO) Files 10-K for the Fiscal Year Ended on December 31, 2018
  7. Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
  8. Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 5, 2019
  9. Aerpio (ARPO) Jumps: Stock Rises 7.8%
  10. Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy
  11. Cincinnati stocks soar as Dow Jones posts one of its five biggest gains ever
  12. Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences — Renewed Outlook, Key Drivers of Growth
  13. Aerpio Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
  14. Aerpio Reports Third Quarter 2018 Financial Results and Provides Business Update
  15. Aerpio Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018
  16. Aerpio Pharmaceuticals Announces Presentation of Renal Function Data from TIME-2 Study of AKB-9778 in Diabetic Retinopathy Patients at American Society of Nephrology Kidney Week 2018
  17. Aerpio Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
  18. Aerpio Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC
  19. The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait
  20. Aerpio Reports Second Quarter 2018 Financial Results and Provides Business Update